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Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne zoonosis 
caused by a Nairovirus (family: Bunyaviridae) and is endemic in 
Africa, the Middle East, Asia and southern Europe.[1,2] Humans 
become infected either directly through the bite of an infected tick 
(mostly Hyalomma spp. or ‘bontpoot’ ticks) or through contact with 
infected animal products, or blood or tissue of infected humans.[1,2] 
Consequently, the majority of CCHF cases occur in individuals who 
live and work in rural farming areas, particularly where livestock 
farming is practised.[1,2] In addition, cases of CCHF in slaughterhouse 
workers and hunters have been reported. Nosocomial transmission of 
CCHF virus has also been reported, albeit infrequently.[3-7] The case 
fatality ratio of CCHF is ~30%.[2] Treatment of CCHF is based on the 
stage of presentation and is mainly supportive.[8] Blood and platelet 
transfusions and in some cases inotropic and ventilatory support are 
typically indicated. Use of the antiviral ribavirin, particularly during 
the early stages of CCHF, has been advocated in cases with a high 
index of suspicion and in patients proven to be suffering from CCHF. 
However, the efficacy of ribavirin in the treatment of CCHF remains 
controversial in the absence of adequate clinical trials.[9-13] Ribavirin is 
a synthetic nucleoside analogue, available only in the oral formation 
in South Africa (SA).
Human cases of CCHF are relatively rare in SA, but have been 
reported from all nine provinces of the country.[3,14] Since the 
first recognition of CCHF in SA in 1981, ~200 human cases have 
been laboratory confirmed in the country (data source: Jacqueline 
Weyer, National Institute for Communicable Diseases, August 2018). 
Historically, the largest numbers of human CCHF cases have occurred 
in the semi-arid livestock farming regions of the Northern Cape, Free 
State and North West provinces. Tick bites have been reported as the 
source of exposure in more than two-thirds of CCHF cases in SA, 
with the remaining cases relating to contact with infected tissues and 
blood (e.g. abattoir workers and hunters).[15] Cases mostly involve 
farmers, farm workers and veterinary health workers.[15]
In a review of CCHF cases reported in SA, fever with bleeding 
was found to be common.[14-16] This was also reported for CCHF 
patients from Eastern Europe, Turkey and the Middle East.[17-23] In 
addition, severe headaches that can be defined as migraines are often 
reported.[14,16-17] Importantly, however, several studies have reported 
diagnosis of CCHF in the absence of fever and/or overt bleeding 
signs.[22,23] Nevertheless, the classic case definition of CCHF (and 
other viral haemorrhagic fever (VHF)) remains primarily based on 
patients presenting with acute onset of fever with bleeding signs and 
a compatible epidemiological history.[24,25] The recognition of unusual 
cases of VHF such as CCHF is problematic, as it implies delays in the 
triggering of infection prevention and control procedures to prevent 
nosocomial exposures and public health responses to identify and 
manage potential contacts and secondary infections.
We report an atypical case of CCHF in SA and present important 
lessons learned through the management of the case.
Case report
A 62-year-old man who farmed sheep, cattle and goats in the north-
eastern Northern Cape Province presented with flu-like symptoms, 
including malaise and dyspnoea, in the winter month of June 2017. 
The patient was known to have type 2 diabetes, benign prostatic 
hyperplasia and hypertension, and was obese. His chronic treatment 
regimen included 500 mg metformin, 4 mg perindopril and 0.4 mg 
tamsulosin daily. Apart from the comorbidities, no recent travel 
history, insect bites (as confirmed by the patient, but also no bite 
marks or eschars were noted on examination) or contact with animals 
known to be sick were reported.
The patient had a 5-day history of progressively worsening 
headache, malaise and myalgia, and had been treated by a general 
practitioner (GP) 3 days before presentation to hospital. He had 
developed tachypnoea, ataxia, polydipsia, anorexia and nausea on 
the day of this consultation. The GP prescribed broad-spectrum oral 
antibiotics and doubled the patient’s metformin dosage.
Because the patient still felt unwell, he referred himself to the 
emergency centre. That day, he was restless and vomited. He was 
apyrexial on admission and was ambulant, and most findings on 
clinical examination were unremarkable. On the way to the hospital 
he cut his finger, and excessive bleeding that was difficult to stem was 
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noted. On initial examination there was marked ecchymosis after 
the non-invasive blood pressure cuff was removed. Initially, the 
patient’s bedside glucose level tested at 18.0 mg/dL, with 1+ ketones 
and 3+ blood on the urine dipstick, with oliguria noted. Further 
bedside testing indicated a metabolic crisis, which was surprising 
given his unremarkable clinical picture (Table 1). Following these 
test results, the initial working diagnosis was a high anion gap 
metabolic acidosis caused by either diabetic ketoacidosis with 
possible sepsis or an inadvertent metformin overdose. Supportive 
treatment was initiated with fluid resuscitation, electrolyte 
abnormality correction, broad-spectrum antibiotics and septic 
work-up. As per the institutional diabetic ketoacidosis protocol, an 
insulin infusion was also initiated.
Formal blood results indicated that the patient was severely 
thrombocytopenic, with a high haemoglobin concentration of 18.0 g/
dL (Table 2). Deranged liver and renal function indicated multisystem 
involvement.
The diagnosis of VHF was considered at this point, given that 
the patient was a farmer with unexplained multiorgan failure and 
coagulopathy, and the institutional CCHF protocol was activated. A 
risk score developed by Swanepoel et al.[14] assigns a score to relevant 
symptoms, signs and investigations to determine the probability of 
CCHF and the need to institute treatment. The patient scored 12, 
which according to this tool requires consideration of CCHF as a 
possible diagnosis even in the absence of fever. The patient continued 
to deteriorate progressively with severe hypotension and tachycardia, 
a worsening pH of 6.7 and unreportable high lactate on a repeat 
venous blood gas profile. Notably, he also started bleeding and oozing 
from venepuncture sites. Inotropic support and a sodium bicarbonate 
bolus were initiated, but the patient had a cardiac arrest and died.
Blood samples were collected post mortem and transferred to 
the National Institute for Communicable Diseases for laboratory 
investigation for VHF. The clinical diagnosis of CCHF was confirmed 
by reverse transcription polymerase chain reaction testing.
Discussion
CCHF is generally considered in the differential diagnosis of a 
patient with fever and bleeding, particularly if an epidemiological 
risk factor (such as a tick bite) is identified.[14,16-23] Atypical cases 
of CCHF have been reported infrequently in published studies. 
Guven et al.[26] described a case of CCHF in a patient who presented 
with hepatorenal failure but no fever. The patient was hypotensive, 
hypothermic, anuric and hypoxic, and had severe metabolic acidosis. 
With no history of tick bites or other predisposing activities reported, 
the patient was scheduled for a liver transplant but died 1 day 
after admission. A diagnosis of CCHF was only considered and 
investigated when a family member of the patient was diagnosed with 
CCHF about a week after the patient’s death. The family members 
had had a picnic together a week before the undiagnosed patient 
became ill, so it is possible that they were in fact exposed to ticks. 
Another report described a patient presenting with acute abdominal 
pain, fever, malaise, headache, vomiting, diarrhoea and bleeding. [27] 
The patient experienced abdominal discomfort on palpation, and 
acute appendicitis was suspected. A laparotomy was performed 
before a diagnosis of CCHF was confirmed in this case. Ardalan et 
al.[28] reported a case involving a young female who was diagnosed 
with thrombocytic microangiopathy and renal failure. Postmortem 
investigations confirmed a diagnosis of CCHF. Cases have also been 
reported where the presence of unrelated symptoms associated with 
comorbid conditions could thwart the CCHF diagnosis, for example a 
CCHF case with previously undiagnosed chronic myeloid leukaemia. 
The patient presented with a clinical picture and exposure history 
Table 1. Summary of point-of-care venous blood gas and 
blood results obtained shortly after admission
Marker Result Reference range
pH 7.01 (low) 7.35 - 7.45
pCO2 (kPa) 5.25 4.66 - 6.38
HCO3 (mmol/L) 10.3 (low) 19 - 24
Base excess (mmol/L) –19.8 (low) –2.0 - 3.0
Urea (mmol/L) 15.4 (high) 2.1 - 7.1
Creatinine (µmol/L) 296 (high) 64 - 104 
Lactate (mmol/L) 18.2 (high) 0.5 - 1
Potassium (mmol/L) 5.7 (high) 3.5 - 4.5
pCO2 = partial pressure of carbon dioxide; HCO3 = bicarbonate. 
Table 2. Formal blood results
Marker Result Reference range
White cell count (× 109/L) 12.73 (high) 3.92 - 10.4
Haemoglobin (g/dL) 18.0 (high) 13.4 - 17.5
Haematocrit (L/L) 0.587 (high) 0.39 - 0.51
Platelet count (× 109/L) 7 (low) 171 - 388
Urea (mmol/L) 16.2 (high) 2.1 - 7.1
Creatinine (µmol/L) 399 (high) 64 - 104 
Calcium (mmol/L) 2.78 (high) 2.15 - 2.50
Magnesium (mmol/L) 1.54 (high) 0.63 - 1.05
Inorganic phosphate (mmol/L) 4.60 (high) 0.78 - 1.42
Alanine transaminase* (IU/L) 547 (high) 10 - 40
Alkaline phosphatase (IU/L) 165 (high) 53 - 128
Gamma-glutamyl transferase (IU/mL) 657 (high) <68
Lactate dehydrogenase (IU/L) 3 557 (high) 100 - 190
Creatine kinase (IU/L) 1 281 (high) <200
C-reactive protein (mg/L) 79 (high) <10.0
International normalised ratio 3.62 (high) 0.8 - 1.2
D-dimer quantitative (mg/L) 3.26 (high) <0.46
Activated partial thromboplastin time (s) 104.1 (high) 30.0 - 40.0
*Aspartate transaminase not tested, sample insufficient.
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compatible with CCHF, but a highly elevated white blood cell count 
(75 × 109/L) and splenomegaly did not fit with that diagnosis.[29] 
The differential diagnosis of CCHF is extensive and in the SA context 
could include, but is not limited to, bacterial septicaemia (with or without 
HIV infection), rickettsiosis, Q fever, listeriosis, infection with hepatitis 
viruses, brucellosis, malaria, meningococcaemia, and if the patient has a 
compatible travel history, other haemorrhagic fever viruses.[14-16]
It is therefore clear that the clinical recognition of CCHF is 
complicated by many factors. Given that CCHF has a case fatality ratio 
of up to 30%, and that the virus has been associated with nosocomial 
transmission in the past, atypical cases resulting in delayed diagnosis 
may have dire consequences. For example, in the case reported by 
Guven et al.,[26] more than 50 healthcare workers were exposed to 
the patient. Intensive public health responses, including case tracing, 
clinical monitoring and provision of ribavirin as prophylaxis, were 
needed to manage and prevent any subsequent cases.
In our case, an atypical presentation (based on initial examination 
and bedside blood results) together with several comorbid factors 
obscured the early diagnosis. In addition, although the patient was 
a farmer from an area where CCHF has been reported previously, 
this event occurred during a winter month when tick activity and 
consequently also the risk of CCHF would be expected to be low. 
Importantly, the patient was apyrexial on examination, and fever is a 
very common finding with CCHF. For example, in a study reviewing 
the clinical features of 160 CCHF patients, fever was noted in 99.4% 
of cases.[30] Since it was reported that the patient had been ill for 5 
days prior to admission, a history of antipyretic use is important to 
consider as a possible reason for apyrexial presentation. Regardless 
of this uncommon presentation, given the fact that the patient was 
a farmer from a CCHF endemic area, the blood results indicating 
multisystem involvement and the clinical presentation (apart from 
no fever), including bleeding signs (ecchymosis, bleeding from 
venepuncture sites), could fit the diagnosis of CCHF. This was 
reiterated by the risk scoring using the Swanepoel criteria,[31] which 
indicated that this patient should be managed as a possible CCHF 
case, and the requirement of specific laboratory testing to confirm 
the diagnosis. The Swanepoel criteria rely on three categories to 
stratify the risk of CCHF in a patient. The categories consist of 
exposure history, signs and symptoms, and findings of laboratory 
investigations. A score of ≥12 points would be an indication to 
manage a patient as a possible case of CCHF. The likelihood of 
certain infectious diseases plummets if there has been no relevant 
context in which exposure may have occurred.
Importantly, the case presented here illustrates that clinicians 
should be wary of the clinically ‘well-looking’ patient with an 
underlying biochemical catastrophe. The epidemiological context of 
the case should not be overlooked. Given CCHF endemicity in SA, 
together with the patient being a farmer from an area where CCHF is 
commonly reported, CCHF was considered as part of the differential 
diagnosis and appropriate infection prevention and control measures 
and other public health responses were triggered promptly. In such a 
case, specific laboratory investigations should be performed as soon 
as possible to confirm or exclude the diagnosis.
Conclusion
It is important for healthcare workers in an area where a rare but 
potentially fatal disease such as CCHF occurs not only to be aware 
of the disease presentation (with possible atypical or confounding 
symptomatology), differential diagnosis and management on a 
professional level, but also to have preparations in place for a 
systematic response in the first few hours, led by the frontline 
personnel, until a district or provincial response gains traction. 
Teaching points
• Re-evaluate patients frequently to assess their response to specific 
treatment interventions. If patients are not responding as expected, 
reconsider the diagnosis and treatment strategy.
• Institutions in at-risk regions for VHF should have clear 
institutional protocols and regular staff training to ensure smooth 
activation of the protocol when needed.
• Always wear protective equipment when dealing with body 
fluids and secretions. Treat all fluids and secretions as potentially 
infectious.
• Common things occur commonly, but occasionally the hoofbeats 
you hear belong to a zebra. Especially in Africa.
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